CrossBridge Bio Secures Seed Funding to Advance Dual-Payload ADC Cancer Therapies

CrossBridge Bio is developing a new class of dual-payload antibody-drug conjugates (ADCs) that deliver multiple therapeutic mechanisms in a single molecule. Based on UTHealth Houston research, the company’s platform aims to improve precision, stability, and safety in cancer treatment. The seed financing supports its lead program, CBB-120, a TROP-2 dual-payload ADC for solid tumors, and the expansion of its oncology pipeline.

Learn more